Gnetin C acts through MTA1/ETS2-mediated mechanisms in prostate cancer and shows significant MTA1-mediated inhibitory effects on cell viability, colony formation and migration, and induces cell cycle arrest and cell death at 25 and 50 μM concentrations. This evidence concerns the gene MTA1 and prostate carcinoma.